PharmaShots | Incisive News in 3 Shots

Subscribe Now

intellia therapeutics

Intellia Therapeutics’ Nexiguran Ziclumeran Secures the US FDA’s RMAT Designation to Treat Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Intellia Therapeutics’ Nexiguran Ziclumeran Secures the US FDA’s RMAT Designation to Treat Hereditary Transthyretin (ATTR) Amyloid...

November 26, 2024

Intellia Therapeutics and ReCode Therapeutics Enter into a Collaboration Agreement to Develop Novel Gene Editing Therapies for Cystic Fibrosis (CF)

Intellia Therapeutics and ReCode Therapeutics Enter into a Collaboration Agreement to Develop Novel Gene Editing Therapies for Cys...

February 17, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us